USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
IOGENETICS, LLC
Address:
IOGENETICS, LLC
3591 ANDERSON ST, #218
MADISON, WI
Phone:
N/A
URL:
N/A
EIN:
391986261
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,090,910.00 2
SBIR Phase II $6,597,525.00 2

Award List:

Antibody-Biocide Fusions to Control Cryptosporidium

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$1,001,223.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this research is develop therapeutic products for Cryptosporidium parvum which can be made at a scale and cost which are feasible for delivery to large populations of patients or individuals at risk, as may be necessary in countering bioterrorism, or… More

Retrovectors for Intron-Enhanced Protein Expression

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$89,687.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Retrovectors are widely used for gene transfer in gene therapy, tissue culture and transgenic animals for research or commercial applications.. A long recognized limitation of current retrovectors is that introns are spliced out as retrovector particles are… More

Antibody-Biocide Fusions to Control Cryptosporidium

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$3,600,017.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this research is develop therapeutic products for Cryptosporidium parvum which can be made at a scale and cost which are feasible for delivery to large populations of patients or individuals at risk, as may be necessary in countering bioterrorism, or… More

Antibody-Biocide Fusions to Control Cryptosporidium

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$2,997,508.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cryptosporidiosis is a leading cause of diarrheal disease worldwide and is a category B biothreat agent. Two major species, Cryptosporidium hominis and Cryptosporidium parvum are responsible for over ninety percent of c ases in man. C. parvum is zoonotic, with a… More